VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
VCEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
VCELVericel Corporation
$46.95$2.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

VCEL logoVericel Corporation(VCEL)Earnings, Financials & Key Ratios

VCEL•NASDAQ
$46.95
146.7× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRegenerative Medicine and Tissue Engineering
AboutVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Show more
  • Revenue$276M+16.5%
  • EBITDA$22M+123.5%
  • Net Income$17M+59.4%
  • EPS (Diluted)0.32+60.0%
  • Gross Margin74.42%+2.6%
  • EBITDA Margin8.11%+92.0%
  • Operating Margin4%+109.9%
  • Net Margin5.98%+36.9%
  • ROE5.11%+27.7%

VCEL Price & Volume

Vericel Corporation (VCEL) stock price & volume — 10-year historical chart

Loading chart...

Specialized Regenerative Therapy Growth Faces Margin Volatility

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Expanding
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Elective procedure demand sensitivity

Key Thesis Takeaways

  • Vericel demonstrates strong commercial traction with 30.1% year-over-year revenue growth in 2026Q1, yet the firm faces significant challenges in achieving consistent operating leverage as SG&A expenses frequently exceed $40 million per quarter.
  • While the company maintains a robust liquidity position with a 5.18 current ratio, the inherent sensitivity of its elective orthopedic procedures to economic cycles warrants caution.
  • Investors should monitor whether the firm can stabilize its erratic free cash flow margins, which have swung from -14.5% to 70.7% over recent periods, to justify its current 144.47 P/E valuation.

Verdict Logic

while the company shows strong top-line growth, the high 144.47 P/E valuation and significant quarterly operating losses, such as the $8.1 million loss in 2026Q1, suggest that the current market price may already account for future scaling potential.

VCEL Growth Metrics

Vericel Corporation (VCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years18.37%
5 Years17.34%
3 Years18.9%
TTM22.45%

Profit CAGR

10 Years-
5 Years41.97%
3 Years-
TTM620.69%

EPS CAGR

10 Years-
5 Years39.49%
3 Years-
TTM1077.4%

Return on Capital

10 Years-12.84%
5 Years-1.97%
3 Years0.54%
Last Year2.69%

VCEL Recent Earnings

Vericel Corporation (VCEL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.12+20.0%
$0.15
Rev
$68M+7.5%
$64M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.45+0.0%
$0.45
Rev
$93M+2.1%
$91M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.10+600.0%
$0.02
Rev
$68M-27.2%
$93M
Q3 2025
Jul 31, 2025
Metric
Actual
Est
EPS
$0.01+75.0%
$0.04
Rev
$63M-2.1%
$65M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.12vs $0.15+20.0%
$68Mvs $64M+7.5%
Q1 2026Feb 26, 2026
$0.45vs $0.45+0.0%
$93Mvs $91M+2.1%
Q4 2025Nov 6, 2025
$0.10vs $0.02+600.0%
$68Mvs $93M-27.2%
Q3 2025Jul 31, 2025
$0.01vs $0.04+75.0%
$63Mvs $65M-2.1%
Based on last 12 quarters of dataView full earnings history →

Latest VCEL News

Recent stock market news and headlines for Vericel Corporation (VCEL)

The Motley Fool·Jun 27, 2026
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.

Peers Comparison

Key metrics vs top competitors for Vericel Corporation (VCEL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
VCEL logoVCELVericel CorporationCurrent
$46.95$2.4B146.7216.45%5.98%5.11%—
MGTX logoMGTXMeiraGTx Holdings plc
$14.66$1.36B-10.32144.57%-151.12%——
RCKT logoRCKTRocket Pharmaceuticals, Inc.
$4.07$444.42M-2.02——-70.79%—
FATE logoFATEFate Therapeutics, Inc.
$3.02$352.01M-2.63-51.24%-2056.79%-58.89%—
AGIO logoAGIOAgios Pharmaceuticals, Inc.
$44.01$2.62B-6.1848.03%-639.84%-34.11%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$17.43$1.96B-4.5716.92%-597.04%-57.27%—

Compare VCEL vs Peers

Vericel Corporation (VCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MGTX

Most directly comparable listed peer for VCEL.

Scale Benchmark

vs SYK

Larger-name benchmark to compare VCEL against a more recognizable public peer.

Peer Set

Compare Top 5

vs MGTX, RCKT, FATE, AGIO

VCEL SEC Filings & Documents

Vericel Corporation (VCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 18, 2026·SEC

Material company update

May 7, 2026·SEC

Material company update

May 1, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Jul 31, 2025·SEC

Get notified when VCEL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

VCEL Frequently Asked Questions

Vericel Corporation (VCEL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Vericel Corporation's revenue?

Vericel Corporation (VCEL) reported $292.1M in revenue for fiscal year 2025. This represents a 18155% increase from $1.6M in 1996.

How fast is Vericel Corporation growing?

Vericel Corporation (VCEL) grew revenue by 16.5% over the past year. This is strong growth.

Is VCEL profitable?

Yes, Vericel Corporation (VCEL) is profitable, generating $21.5M in net income for fiscal year 2025 (6.0% net margin).

Dividend & Returns
What is VCEL's return on equity?

Vericel Corporation (VCEL) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.

What is Vericel Corporation's free cash flow?

Vericel Corporation (VCEL) generated $57.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in VCEL back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →